Details of the Drug

General Information of Drug (ID: DM27H0P)

Drug Name
Collategene
Indication
Disease Entry ICD 11 Status REF
Peripheral Ischemic Ulcers BD41 Phase 2 [1]
Drug Type
Gene therapy
Cross-matching ID
TTD ID
DNHW41

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Hepatocyte growth factor (HGF) TT4V2JM HGF_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Peripheral Ischemic Ulcers
ICD Disease Classification BD41
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Hepatocyte growth factor (HGF) DTT HGF 4.90E-01 0.13 2.73
Hepatocyte growth factor (HGF) DTT HGF 1.98E-07 1.58 2.92
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04267640) A Phase II Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of AMG0001 to Improve Ulcer Healing and Perfusion in Subjects Who Have Peripheral Ischemic Ulcers of the Lower Extremity. U.S.National Institutes of Health.
2 Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia. Gene Ther. 2010 Sep;17(9):1152-61.